Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.During consultancy phase SynCo to assist the client with in-house process development
Subscribe to our email newsletter
SynCo Bio Partners has signed a contract to manufacture a live biotherapeutic with a Japanese pharmaceutical company.
The undisclosed company’s product is a live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development.
In addition, the developed process will then be transferred to SynCo’s Amsterdam facility and scaled-up, prior to GMP manufacture for phase I clinical trials, including fermentation, formulation and aseptic filling.
Pierre Warffemius, CEO at SynCo, said: We are extremely pleased to be working with our first Japanese partner. I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics.